NO20061252L - Doseringsplan for ERBB2 antikreftmidler - Google Patents

Doseringsplan for ERBB2 antikreftmidler

Info

Publication number
NO20061252L
NO20061252L NO20061252A NO20061252A NO20061252L NO 20061252 L NO20061252 L NO 20061252L NO 20061252 A NO20061252 A NO 20061252A NO 20061252 A NO20061252 A NO 20061252A NO 20061252 L NO20061252 L NO 20061252L
Authority
NO
Norway
Prior art keywords
erbb2
mammal
inhibitor
anticancer agents
dosage schedule
Prior art date
Application number
NO20061252A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Damian Connell
Samit Kumar Bhattacharya
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Noe
Stefanus Johannes Steyn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20061252L publication Critical patent/NO20061252L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20061252A 2003-08-18 2006-03-17 Doseringsplan for ERBB2 antikreftmidler NO20061252L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18
PCT/IB2004/002580 WO2005016347A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Publications (1)

Publication Number Publication Date
NO20061252L true NO20061252L (no) 2006-05-16

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061252A NO20061252L (no) 2003-08-18 2006-03-17 Doseringsplan for ERBB2 antikreftmidler

Country Status (18)

Country Link
US (1) US20050119288A1 (pt)
EP (1) EP1658080A1 (pt)
JP (1) JP2007502807A (pt)
KR (2) KR20080014144A (pt)
CN (1) CN1838959A (pt)
AR (1) AR045268A1 (pt)
AU (1) AU2004264726A1 (pt)
BR (1) BRPI0413745A (pt)
CA (1) CA2536140A1 (pt)
CO (1) CO5670356A2 (pt)
IL (1) IL173127A0 (pt)
MX (1) MXPA06001989A (pt)
NO (1) NO20061252L (pt)
RU (1) RU2328287C2 (pt)
SG (1) SG135193A1 (pt)
TW (1) TW200522966A (pt)
WO (1) WO2005016347A1 (pt)
ZA (1) ZA200600517B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
JP4828421B2 (ja) * 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
MXPA06003113A (es) 2003-09-19 2006-06-20 Astrazeneca Ab Derivados de quinazolina.
AP2204A (en) * 2004-05-06 2011-02-07 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides.
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
EP1896030A1 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
JP5235662B2 (ja) * 2005-06-16 2013-07-10 ミリアド ジェネティクス， インコーポレイテッド 薬学的組成物およびその使用
JP2009502960A (ja) * 2005-07-27 2009-01-29 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ
US8945573B2 (en) * 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CN102579467A (zh) * 2005-11-14 2012-07-18 阿里亚德医药股份有限公司 雷帕霉素衍生物在治疗癌症中的用途
CA2755268C (en) * 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
AU2007241130A1 (en) * 2006-03-31 2007-11-01 EMD Serono Research Centre, Inc. Treatment of tumors expressing mutant EGF receptors
WO2007115286A2 (en) * 2006-04-05 2007-10-11 Novartis Ag. Combinations of therapeutic agents for treating cancer
CA2669415A1 (en) 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
KR20100016385A (ko) * 2007-04-10 2010-02-12 미리어드 파마슈티칼스, 인코포레이티드 뇌종양 치료방법
AU2008236997A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
CA2690334C (en) * 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US8252805B2 (en) * 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
US20130209543A1 (en) * 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
CN110564604B (zh) 2014-01-31 2023-09-29 凸版印刷株式会社 液滴的形成方法、生物分子分析方法及生物分子分析试剂盒
HK1259311A1 (zh) * 2015-10-28 2019-11-29 Tva (Abc), Llc Sstr靶向綴合物及其顆粒和製劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
NZ522568A (en) * 2000-06-22 2004-12-24 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
AP2004003059A0 (en) * 2001-12-12 2004-06-30 Pfizer Prod Inc Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
IL161908A0 (en) * 2001-12-12 2005-11-20 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
EP1567506A4 (en) * 2002-11-20 2007-06-20 Array Biopharma Inc CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
EP1575592A1 (en) * 2002-12-18 2005-09-21 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
AU2004264726A1 (en) 2005-02-24
BRPI0413745A (pt) 2006-10-24
EP1658080A1 (en) 2006-05-24
CO5670356A2 (es) 2006-08-31
KR20080014144A (ko) 2008-02-13
CN1838959A (zh) 2006-09-27
RU2006102125A (ru) 2007-09-27
KR20060037447A (ko) 2006-05-03
SG135193A1 (en) 2007-09-28
AR045268A1 (es) 2005-10-19
US20050119288A1 (en) 2005-06-02
CA2536140A1 (en) 2005-02-24
RU2328287C2 (ru) 2008-07-10
IL173127A0 (en) 2006-06-11
ZA200600517B (en) 2007-02-28
WO2005016347A1 (en) 2005-02-24
MXPA06001989A (es) 2006-05-17
JP2007502807A (ja) 2007-02-15
TW200522966A (en) 2005-07-16

Similar Documents

Publication Publication Date Title
SG135193A1 (en) Dosing schedule for erbb2 anticancer agents
ZA202109010B (en) Compounds and methods for the treatment of covid-19
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
RU2010133480A (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
RU2012111823A (ru) Ферментная заместительная терапия с увеличением дозы для лечения недостаточности кислой сфингомиелиназы
NO20092150L (no) Fremgangsmater for behandling av hyperkolesterolemi
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MY169275A (en) Method of immunization against the four serotypes of dengue
WO2010141842A3 (en) Interlaced method for treating cancer or a precancerous condition
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
UA81625C2 (ru) Применение ротиготина для трансепикутального лечения синдрома уставших ног
MX2009012093A (es) Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
IL307516A (en) Tremor treatment
BR0014166A (pt) Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
TW200639159A (en) Treatment of pain
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
TW200719903A (en) Compositions for the treatment of neoplasms
MX2010002679A (es) Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
NO20063320L (no) Anvendelse av gaboxadol for behandling av insomni
MX2023008796A (es) Métodos para el tratamiento del trastorno del habla en niños.
TW200635609A (en) Novel pharmaceutical composition containing at least one dolastatin 10 derivative

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application